Biotech Focuses on Gene Therapy for Huntington’s, Heart Disease, Hemophilia B
Nov 17, 2016 10:35 am | Charles Moore
Gene therapy biotech uniQure is prioritizing its drug pipeline to develop treatments for Huntington’s disease, hemophilia B, and its partnered gene therapy programs associated with uniQure’s collaboration with Bristol-Myers Squibb (BMS) in cardiovascular disease. The company will restructure its research and development organization in the Netherlands and consolidate manufacturing in the United States to reduce operating expenses […]
The post Biotech Focuses on Gene Therapy for Huntington’s, Heart Disease, Hemophilia B appeared first on Huntington's Disease News.